Vecuronium bromide
 | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Metabolism | liver 30% |
| Elimination half-life | 51–80 minutes (longer with renal failure) |
| Excretion | Fecal (40-75%) and renal (30% as unchanged drug and metabolites) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.549 |
| Chemical and physical data | |
| Formula | C34H57N2O4+ |
| Molar mass | 557.827 g/mol g·mol−1 |
| (verify) | |
Vecuronium (Norcuron) is a muscle relaxant in the category of non-depolarizing blocking agents. Vecuronium bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Although vecuronium bromide is often thought of as a muscle relaxant, it may be more accurate to classify it as a paralyzing agent. It is commercially available as ampoules containing 4 mg of the drug in powder form which needs to be dissolved in distilled water prior to administration to the patient. In India, vials containing 10 mg of vecuronium bromide are also commercially available, for use in patients undergoing prolonged surgical procedures.
Development
Vecuronium's structure is derived from the same aminosteroid structure as Pancuronium, but missing the methyl group on the piperidine nitrogen that is attached to the 'A' ring making it monoquaternary, like d-Tubocurarine. This means it is less potent than Pancuronium as a neuromuscular blocking agent. It has the same configuration at all ten stereocentres as Pancuronium and is a single-isomer preparation.
Clinical pharmacology
Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia. Under balanced anesthesia, the time to recovery to 25% of control (clinical duration) is approximately 25 to 40 minutes after injection and recovery is usually 95% complete approximately 45 to 65 minutes after injection of intubating dose. The neuromuscular blocking action of vecuronium is slightly enhanced in the presence of potent inhalation anesthetics. If vecuronium is first administered more than 5 minutes after the start of the inhalation of enflurane, isoflurane, or halothane, or when a steady state has been achieved, the intubating dose of vecuronium may be decreased by approximately 15%.
Vecuronium is an aminosteroid.
In the news
In 2001, Japanese nurse Daisuke Mori was reported to have murdered 10 patients using vecuronium bromide.[2] He was convicted of a murder and was sentenced to life imprisonment.[3]
See also
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Japanese nurse kills 10 patients, says wanted to trouble hospital". The Indian Express. 2001-01-10. Retrieved 2008-03-22.
- ^ "Top court dismisses appeal by ex-nurse over Sendai clinic murder". Breitbart.com. 2008-02-27. Retrieved 2008-03-22.